Evidence map›Paper›PMID 33672029›Full record

ArticleMolecules (Basel, Switzerland)2021

Formulation of Novel Liquid Crystal (LC) Formulations with Skin-Permeation-Enhancing Abilities of

Dóra Kósa, Ágota Pető, Ferenc Fenyvesi, Judit Váradi, Miklós Vecsernyés, Sándor Gonda, Gábor Vasas, Pálma Fehér, Ildikó Bácskay, Zoltán Ujhelyi

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Bridging bioactive metabolites ofFrontiers in pharmacology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Dóra KósaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.
Ágota PetőDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.
Ferenc FenyvesiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.ORCID 0000-0003-2890-0783
Judit VáradiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.
Miklós VecsernyésDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.ORCID 0000-0001-5719-975X
Sándor GondaDepartment of Botany, Faculty of Science and Technology, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.ORCID 0000-0001-9776-0249
Gábor VasasDepartment of Botany, Faculty of Science and Technology, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.
Pálma FehérDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.
Ildikó BácskayDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.ORCID 0000-0001-8663-2890
Zoltán UjhelyiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei körút 98, 4032 Debrecen, Hungary.ORCID 0000-0001-9724-0614
University of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exposure to reactive oxygen species can easily result in serious diseases, such as hyperproliferative skin disorders or skin cancer. Herbal extracts are widely used as antioxidant sources in different compositions. The importance of antioxidant therapy in inflammatory conditions has increased. Innovative formulations can be used to improve the effects of these phytopharmacons. The bioactive compounds of

Indexed as

Drug CompoundingBiphenyl CompoundsCell ProliferationCell SurvivalElectric ImpedanceFree Radical ScavengersHaCaT CellsHumansLipid PeroxidationLiquid CrystalsMalondialdehydePermeabilityPicratesPlantagoPlant ExtractsSkin1,1-diphenyl-2-picrylhydrazylBiphenyl CompoundsFree Radical ScavengersMalondialdehydePicratesPlant Extractsantioxidant and anti-inflammatory effectscytotoxicity investigationDPPH testHaCaT cellsliquid crystalsMDAMTT testpenetration enhancersPlantago lanceolataROSRTCATEER

Identifiers

PMID33672029
PMCPMC7919469
OpenAlexW3130045714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.